Results 11 to 20 of about 116,907 (303)
Thrombotic microangiopathy in children [PDF]
Pediatric Nephrology, 2022 The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ involvement.
L. Palma +4 more
semanticscholar +4 more sources
Complement in Secondary Thrombotic Microangiopathy [PDF]
Kidney International Reports, 2020 Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the setting of normal international normalized ratio and activated partial thromboplastin time.
L. Palma, Meera Sridharan, S. Sethi
semanticscholar +5 more sources
Pulmonary tumor thrombotic microangiopathy: a systematic review. [PDF]
Pulmonary Circulation, 2019 Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal disease process in which pulmonary hypertension (PH) develops in the setting of malignancy.
Ben Khelil M +8 more
core +2 more sources
Thrombotic microangiopathy in oncology – a review
Translational Oncology, 2021 Thrombotic microangiopathy is a syndrome triggered by a wide spectrum of situations, some of which are specific to the Oncology setting. It is characterized by a Coombs-negative microangiopathic haemolytic anemia, thrombocytopenia and organ injury, with characteristic pathological features, resulting from platelet microvascular occlusion.
P. Valério +5 more
semanticscholar +4 more sources
Thrombotic Microangiopathies [PDF]
ISRN Hematology, 2012 Thrombotic microangiopathy results from thrombotic occlusion of the microvasculature leading to fragmentation of red blood cells, profound thrombocytopenia, and a microangiopathic hemolytic anemia with elevation of lactate dehydrogenase and negative direct Coomb’s test.
Radhi, Mohamed, Carpenter, Shannon L.
openaire +4 more sources
Journal of Clinical Investigation, 2023 BACKGROUND Systemic administration of adeno-associated virus (AAV) can trigger life-threatening inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypical hemolytic uremic syndrome–like complement activation ...
S. Salabarria +14 more
semanticscholar +1 more source
Frontiers in Pharmacology, 2023 Drug-induced thrombotic microangiopathy (DITMA) represents 10%–13% of all thrombotic microangiopathy (TMA) cases and about 20%–30% of secondary TMAs, just behind pregnancy-related and infection-related forms.
Tommaso Mazzierli +3 more
semanticscholar +1 more source
Chemotherapy-Associated Thrombotic Microangiopathy
Kidney360, 2023 Thrombotic microangiopathy (TMA) is a syndrome of microangiopathic hemolytic anemia and thrombocytopenia with end-organ dysfunction. Although the advent of plasma exchange, immunosuppression, and complement inhibition has improved morbidity and mortality
Abinet M. Aklilu, A. Shirali
semanticscholar +1 more source
Clinical Evaluation and Management of Thrombotic Microangiopathy
Arthritis & Rheumatology, 2023 Thrombotic microangiopathy (TMA) refers to a diverse group of diseases that share clinical and histopathologic features. TMA is clinically characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and organ injury that stems from ...
Joshua Leisring, S. Brodsky, S. Parikh
semanticscholar +1 more source
Renal Thrombotic Microangiopathy: A Review.
American Journal of Kidney Diseases, 2022 Thrombotic microangiopathy (TMA) is a pathological lesion observed in a wide spectrum of diseases, triggered by endothelial injury and/or dysfunction. Although TMA lesions are often accompanied by clinical features of microangiopathic hemolytic anemia ...
D. Genest +4 more
semanticscholar +1 more source